VivoSeq
Other

Weight Gain

3

Pipeline Programs

3

Active Trials

6

Companies Involved

Weight Gain is an early-stage landscape with 3 programs across 6 companies. The most active players are Gilead, GSK, Corcept Therapeutics.

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

77/100

Attrition Rate

21/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Approved
No programs

Trial Status

34

clinical trials

Completed23 · 68%
Terminated6 · 18%
Recruiting2 · 6%
Not yet recruiting1 · 3%
Withdrawn1 · 3%
Unknown status1 · 3%

Trial Activity

34 trials

Delivering HOPE (Helping Women Optimize Prenatal Equity)
Recruiting·UUniversity of Arkansas·Preclinical·NCT06814509·1,440 enrolled
Weight Gain Prevention in Adolescents and Young Adults
Not yet recruiting·UUniversity of Minnesota·Phase 3·NCT06905626·140 enrolled
Medication, Weight Gain and GI Hormones
Completed·VVanderbilt University·Phase 4·NCT00384332·20 enrolled
Naltrexone for Antipsychotic-Induced Weight Gain
Completed·YYale University·N/A·NCT01866098·144 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)